Nifty 17277.95 (0.75%)
Sensex 57858.15 (0.64%)
Nifty Bank 37706.75 (2.05%)
Nifty IT 34707.45 (-0.33%)
Nifty Financial Services 17789.8 (0.89%)
Adani Ports 711.10 (1.23%)
Asian Paints 3147.10 (-0.26%)
Axis Bank 752.20 (6.76%)
B P C L 382.55 (2.53%)
Bajaj Auto 3469.10 (2.57%)
Bajaj Finance 6963.75 (0.46%)
Bajaj Finserv 15528.95 (-1.13%)
Bharti Airtel 711.85 (3.18%)
Britannia Inds. 3539.30 (0.44%)
Cipla 905.65 (1.52%)
Coal India 161.15 (3.10%)
Divis Lab. 4049.20 (-0.18%)
Dr Reddys Labs 4402.85 (0.88%)
Eicher Motors 2692.00 (1.34%)
Grasim Inds 1721.30 (1.81%)
H D F C 2530.60 (-0.36%)
HCL Technologies 1123.70 (-0.11%)
HDFC Bank 1488.05 (0.09%)
HDFC Life Insur. 630.80 (0.51%)
Hero Motocorp 2782.05 (2.80%)
Hind. Unilever 2327.25 (1.87%)
Hindalco Inds. 485.75 (1.54%)
I O C L 121.45 (0.91%)
ICICI Bank 801.65 (0.40%)
IndusInd Bank 884.25 (3.88%)
Infosys 1722.15 (-0.84%)
ITC 214.30 (1.18%)
JSW Steel 631.15 (1.50%)
Kotak Mah. Bank 1854.65 (1.30%)
Larsen & Toubro 1925.30 (1.34%)
M & M 854.50 (-0.02%)
Maruti Suzuki 8602.60 (6.83%)
Nestle India 18790.75 (0.39%)
NTPC 135.30 (2.04%)
O N G C 165.15 (-0.33%)
Power Grid Corpn 218.85 (2.27%)
Reliance Industr 2373.25 (-0.20%)
SBI Life Insuran 1228.00 (0.24%)
Shree Cement 24497.50 (0.73%)
St Bk of India 514.65 (4.15%)
Sun Pharma.Inds. 808.05 (0.90%)
Tata Consumer 707.75 (2.36%)
Tata Motors 490.55 (2.53%)
Tata Steel 1109.10 (0.90%)
TCS 3769.90 (-0.04%)
Tech Mahindra 1500.60 (-0.83%)
Titan Company 2376.50 (-1.10%)
UltraTech Cem. 7098.35 (-0.81%)
UPL 791.15 (3.74%)
Wipro 562.70 (-1.75%)

Glenmark Life Sciences IPO: Getting a share of the global API market

Glennmark life science IPO

Glenmark Life Sciences joined the list of big ticket IPOs making a public offer. The company was incorporated in 2011 as a wholly-owned subsidiary of Glenmark Pharma. Indian Pharma industry is divided into Active Pharma Ingredients (APIs), CRAMs and Generics. Glenmark Life is a key player in the API space and in India it competes with other names like Divi’s Labs, Laurus Labs, Aarti Drugs, Granules etc. Global PE players like Advent, Carlyle and KKR have shown keen interest in API companies. It is in this background that the Glenmark Life Sciences IPO has been announced.


Key terms of the IPO of Glenmark Life Sciences

The total issue size of Rs.1,514 crore will consist of a fresh issue of Rs.1,060 crore and an offer-for-sale by Glenmark Pharma to the tune of Rs.454 crore. Here is a quick IPO summary.


Key IPO Details


Nature of issue

Book Building

Face value of share

Rs.2 per share

IPO Price Band

Rs.695 - Rs.720

Market Lot


Retail Investment limit

13 Lots (260 shares)

Retail limit - Value


Fresh Issue Size

Rs.1,060 crore

Offer for Sale Size

Rs.454 crore

Total IPO Size

Rs.1,514 crore

Listing on


QIB Quota


Data Source: IPO Filings


Read: 5 Reasons to invest in Glenmark Life Sciences IPO

Glenmark Life Sciences IPO Dates -

Key IPO Details


Issue Opens on

27th Jul 2021

Issue Closes on

29th Jul 2021

Basis of Allotment date

03rd Aug 2021

Refund Initiation date

04th Aug 2021

Credit to Demat

05th Aug 2021

IPO Listing date

06th Aug 2021

Pre issue promoter stake


Peer Group

Divi, Laurus, Granules

Indicative Market Cap

Rs.8,820 crore

HNI Quota


Retail Quota


Data Source: IPO Filings

Understanding the business model of Glenmark Life Sciences 

It is estimated that in the overall valuation of Glenmark Pharma, 35-40% value comes from Glenmark Life Sciences; a substantial chunk. Here is a key to the business model of Glenmark Life Sciences.
•    Glenmark Life develops APIs for specialized uses like in cardio vascular diseases, central nervous system diseases, pain management, diabetes and gastrointestinal disorders. APIs are the equivalent of specialized inputs that go into the manufacture of medicines and India and China have enjoyed an established leadership in this segment.

•    The API trend shifted towards India in the last couple of years after China tightened environmental norms for its bulk drug and chemical companies. Global pharma companies also preferred to diversify their dependence on China, and India offered an option. This opened up a huge opportunity for Indian API manufacturers.

•    If Active Pharma Ingredients (APIs) are one big segment of Glenmark Life, the other key segment is Contract Development and Manufacturing Operations (CDMO). This is another fast growing business which offers specialized high-end services to global pharma companies on a contract basis.

•    Glenmark Life is a leading API manufacturer for CVD, CNS and pain management via its 4 manufacturing facilities with a combined capacity of 726 KL. Glenmark Life exports to the Americas, Europe and Japan with long standing relations with top generic players.


Read: 6 Facts to Know Before Investing in Glenmark Life Sciences IPO

Glenmark Life Sciences' Financials – Smart growth, solid margins

Glenmark Life has presented a strong growth story and offers a macro play on the API growth in India. Sales more than doubled from Rs.887 crore in FY19 to Rs.1,886 crore in FY21. The asset turnover ratio (a key driver of profitability) has improved from 0.60 in FY19 to 0.94 in FY21.

Glenmark Life Sciences saw net profits growing 80% in last 2 years from Rs.196 crore in FY19 to Rs.352 crore in FY21. Over the last 3 years, the net profit margins have been 22.1%, 20.2% and 18.87%. During the same 3 years, the return on assets (ROA) were 13.3%, 18.1% and 17.6%. In short, return ratios have been robust and stable in last 3 years.

Look at Glenmark Life Sciences as a macro play on API opportunity

a)    When you invest in an idea look at what the leaders are doing. In the last 1 year, PE funds like KKR, Chrysalis, Advent and Carlyle have infused $1.5 billion into Indian API players. This year, they are cutting a cheque of $4 billion. Clearly the story is huge.

b)    The IPO upper price band values the stock at over 25X P/E ratio on FY21 EPS. However, the annualized growth in profits and revenues has been much more than that. This is lower than peer group valuations and should look better with forward earnings.

c)    APIs is really the story of what the Indian pharma industry is really likely to specialize, differentiate and deliver in the next 5 years. That is where Glenmark Life Sciences is positioned making it a highly attractive proposition.

Execution is the key in the API business, but the valuations and the virtually unlimited API opportunity for Indian companies, does make Glenmark Life IPO a compelling proposition.

About the Author

Open Demat Account

Enter Mobile Number
Enter correct otp
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
366.64 (0.64%)
Nifty 50
128.85 (0.75%)
Nifty Bank
759.20 (2.05%)
Next Article

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number

Stocks Directory

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9